propafenone has been researched along with Heart Disease, Ischemic in 12 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 9.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "During myocardial ischemia, particularly during LAD occlusion, propafenone results in a significant increase in QT dispersion." | 9.08 | Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. ( Daisenberger, K; Faber, TS; Just, H; Krahnefeld, O; Meinertz, T; Zehender, M, 1997) |
| "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias." | 8.79 | Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. ( Boriani, G; Capucci, A, 1995) |
| "Oral propafenone hydrochloride effect was studied on atrial signal-averaged ECG (ASAECG) during time- and frequency-domain analysis in patients with paroxysmal atrial fibrillation (PAF) during ischemic heart disease (IHD)." | 5.08 | [Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation]. ( Banasiak, W; Fuglewicz, A; Kałka, D; Lacheta, W; Molenda, W; Pieróg, M; Ponikowski, P; Telichowski, A; Wiech, K; Zebrowski, J, 1995) |
| "During myocardial ischemia, particularly during LAD occlusion, propafenone results in a significant increase in QT dispersion." | 5.08 | Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. ( Daisenberger, K; Faber, TS; Just, H; Krahnefeld, O; Meinertz, T; Zehender, M, 1997) |
| "Propafenone is a potent antiarrhythmic agent effective in either supraventricular or ventricular tachyarrhythmias." | 4.79 | Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal. ( Boriani, G; Capucci, A, 1995) |
| " In 11 dogs the effects of myocardial ischemia, premature epicardial stimulation (PES) and propafenone on anisotropic conduction properties were tested using three-dimensional mapping techniques." | 3.72 | Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts. ( Bauer, A; Becker, R; Kraft, P; Kuebler, W; Schoels, W; Schreiner, KD; Senges, JC; Voss, F, 2003) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (75.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Bauer, A | 1 |
| Becker, R | 1 |
| Voss, F | 1 |
| Senges, JC | 1 |
| Kraft, P | 1 |
| Schreiner, KD | 1 |
| Kuebler, W | 1 |
| Schoels, W | 1 |
| Ye, VZ | 1 |
| Wyse, KR | 1 |
| Campbell, TJ | 1 |
| Palazzuoli, V | 2 |
| Mondillo, S | 2 |
| Faglia, S | 2 |
| D'Aprile, N | 2 |
| Camporeale, A | 1 |
| Gennari, C | 1 |
| Capucci, A | 1 |
| Boriani, G | 1 |
| Aupetit, JF | 1 |
| Timour, Q | 1 |
| Larbre, JP | 1 |
| Loufoua-Moundanga, J | 1 |
| Kioueh, I | 1 |
| Lopez, M | 1 |
| Faucon, G | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 1 |
| Ponikowski, P | 1 |
| Wiech, K | 1 |
| Zebrowski, J | 1 |
| Pieróg, M | 1 |
| Kałka, D | 1 |
| Lacheta, W | 1 |
| Fuglewicz, A | 1 |
| Molenda, W | 1 |
| Mangiacotti, L | 1 |
| Campolo, MA | 1 |
| Agricola, E | 1 |
| Faber, TS | 1 |
| Zehender, M | 1 |
| Krahnefeld, O | 1 |
| Daisenberger, K | 1 |
| Meinertz, T | 1 |
| Just, H | 1 |
| Pelter, MM | 1 |
| Adams, MG | 1 |
| Nakamura, T | 1 |
| Kashimoto, S | 1 |
| Oguchi, T | 1 |
| Kumazawa, T | 1 |
2 reviews available for propafenone and Heart Disease, Ischemic
| Article | Year |
|---|---|
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Electrophysiology; Female; | 1995 |
5 trials available for propafenone and Heart Disease, Ischemic
| Article | Year |
|---|---|
[The evaluation of the antiarrhythmic activity of L-carnitine and propafenone in ischemic cardiopathy].
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Carnitine; Drug Therapy, Combination; El | 1993 |
[Effect of propafenone hydrochloride on atrial signal-averaged ECG in patients with paroxysmal atrial fibrillation].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Electrocar | 1995 |
[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Drug Sy | 1995 |
Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Female; Heart Conduct | 1997 |
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
5 other studies available for propafenone and Heart Disease, Ischemic
| Article | Year |
|---|---|
Effects of acute ischemia, early extrabeats and propafenone on complex activation patterns in intact and ischemic canine hearts.
Topics: Animals; Anisotropy; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Elect | 2003 |
Lidocaine shows greater selective depression of depolarized and acidotic myocardium than propafenone: possible implications for proarrhythmia.
Topics: Action Potentials; Analysis of Variance; Animals; Arrhythmias, Cardiac; Female; Guinea Pigs; Heart; | 1993 |
Arrhythmogenicity of antiarrhythmic drugs and intraventricular conduction disorders: possible aggravation by myocardial ischemia--study in the porcine in situ heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; | 1993 |
Giant inverted T waves.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Humans; Male; Myocardial Is | 2001 |
Effects of propafenone on function and metabolism in the ischemic working rat heart.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Energy Metabolism; Heart Rate; Hemodynamics; Male; | 1992 |